Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.

Scholl C, Fröhling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, Döhner K, Bullinger L, Sandy P, Boehm JS, Root DE, Jacks T, Hahn WC, Gilliland DG.

Cell. 2009 May 29;137(5):821-34. doi: 10.1016/j.cell.2009.03.017.

2.

Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.

Wang Y, Kaiser CE, Frett B, Li HY.

J Med Chem. 2013 Jul 11;56(13):5219-30. doi: 10.1021/jm3017706. Epub 2013 Apr 23. Review.

3.

Screen for Inhibitors of STK33 Kinase Activity.

Spoonamore J, Weïwer M, Wei J, Guichard B, Ross NT, Masson K, Silkworth W, Dandapani S, Munoz B, Palmer M, Scherer C, Schreiber SL.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2011 Dec 16 [updated 2014 May 13].

4.

Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers.

Ebi H, Faber AC, Engelman JA, Yano S.

Cancer Sci. 2014 May;105(5):499-505. doi: 10.1111/cas.12383. Epub 2014 Mar 26. Review.

5.

GI-4000 in KRAS mutant cancers.

Shahda S, O'Neil B.

Expert Opin Investig Drugs. 2014 Feb;23(2):273-8. doi: 10.1517/13543784.2014.876408. Epub 2013 Dec 30. Review.

PMID:
24372276
6.

The end of KRAS, and other, cancers? A new way forward.

Mallucci L, Wells V.

Drug Discov Today. 2014 Apr;19(4):383-7. doi: 10.1016/j.drudis.2013.11.018. Epub 2013 Nov 27. Review.

PMID:
24291216
7.

KRAS mutations in non-small cell lung cancer.

Riely GJ, Marks J, Pao W.

Proc Am Thorac Soc. 2009 Apr 15;6(2):201-5. doi: 10.1513/pats.200809-107LC. Review.

PMID:
19349489
8.

RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?

Downward J.

Clin Cancer Res. 2015 Apr 15;21(8):1802-9. doi: 10.1158/1078-0432.CCR-14-2180. Review.

9.

Applying synthetic lethality for the selective targeting of cancer.

McLornan DP, List A, Mufti GJ.

N Engl J Med. 2014 Oct 30;371(18):1725-35. doi: 10.1056/NEJMra1407390. Review. No abstract available.

PMID:
25354106
10.

Current views on inducing synthetic lethal RNAi responses in the treatment of cancer.

Kacsinta AD, Dowdy SF.

Expert Opin Biol Ther. 2016;16(2):161-72. doi: 10.1517/14712598.2016.1110141. Epub 2015 Dec 2. Review.

PMID:
26630128
11.

Drugging the addict: non-oncogene addiction as a target for cancer therapy.

Nagel R, Semenova EA, Berns A.

EMBO Rep. 2016 Nov;17(11):1516-1531. Epub 2016 Oct 4. Review.

12.

KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach.

de Castro Carpeño J, Belda-Iniesta C.

Transl Lung Cancer Res. 2013 Apr;2(2):142-51. doi: 10.3978/j.issn.2218-6751.2013.02.07. Review.

13.

Therapeutic Approaches to RAS Mutation.

Scott AJ, Lieu CH, Messersmith WA.

Cancer J. 2016 May-Jun;22(3):165-74. doi: 10.1097/PPO.0000000000000187. Review.

14.

An intermittent approach for cancer chemoprevention.

Wu X, Lippman SM.

Nat Rev Cancer. 2011 Nov 10;11(12):879-85. doi: 10.1038/nrc3167. Review.

PMID:
22071977
15.

Pharmacological treats for SUMO addicts.

Licciardello MP, Kubicek S.

Pharmacol Res. 2016 May;107:390-397. doi: 10.1016/j.phrs.2016.01.004. Epub 2016 Jan 24. Review.

PMID:
26816086
16.

Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements.

Mizuarai S, Kotani H.

Hum Genet. 2010 Dec;128(6):567-75. doi: 10.1007/s00439-010-0900-x. Epub 2010 Oct 26. Review.

PMID:
20976469

Supplemental Content

Support Center